Literature DB >> 11517213

HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2.

M Metzler1, V Legendre-Guillemin, L Gan, V Chopra, A Kwok, P S McPherson, M R Hayden.   

Abstract

Polyglutamine expansion in huntingtin is the underlying mutation leading to neurodegeneration in Huntington disease. This mutation influences the interaction of huntingtin with different proteins, including huntingtin-interacting protein 1 (HIP1), in which affinity to bind to mutant huntingtin is profoundly reduced. Here we demonstrate that HIP1 colocalizes with markers of clathrin-mediated endocytosis in neuronal cells and is highly enriched on clathrin-coated vesicles (CCVs) purified from brain homogenates. HIP1 binds to the clathrin adaptor protein 2 (AP2) and the terminal domain of the clathrin heavy chain, predominantly through a small fragment encompassing amino acids 276-335. This region, which contains consensus clathrin- and AP2-binding sites, functions in conjunction with the coiled-coil domain to target HIP1 to CCVs. Expression of various HIP1 fragments leads to a potent block of clathrin-mediated endocytosis. Our findings demonstrate that HIP1 is a novel component of the endocytic machinery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517213     DOI: 10.1074/jbc.C100401200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Does clathrin pull the fission trigger?

Authors:  Gilbert Di Paolo; Pietro De Camilli
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

Review 2.  Clathrin-dependent endocytosis.

Authors:  Seyed Ali Mousavi; Lene Malerød; Trond Berg; Rune Kjeken
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

3.  Clathrin is important for normal actin dynamics and progression of Sla2p-containing patches during endocytosis in yeast.

Authors:  Thomas M Newpher; Sandra K Lemmon
Journal:  Traffic       Date:  2006-05       Impact factor: 6.215

4.  Crystal structure at 2.8 A of the DLLRKN-containing coiled-coil domain of huntingtin-interacting protein 1 (HIP1) reveals a surface suitable for clathrin light chain binding.

Authors:  Joel A Ybe; Sanjay Mishra; Stephen Helms; Jay Nix
Journal:  J Mol Biol       Date:  2006-12-23       Impact factor: 5.469

5.  Clathrin-mediated post-Golgi membrane trafficking in the morphogenesis of hepatitis delta virus.

Authors:  Cheng Huang; Shin C Chang; Hui-Chin Yang; Chung-Liang Chien; Ming-Fu Chang
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

6.  Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival.

Authors:  Dinesh S Rao; Teresa S Hyun; Priti D Kumar; Ikuko F Mizukami; Mark A Rubin; Peter C Lucas; Martin G Sanda; Theodora S Ross
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 7.  Peptide motifs: building the clathrin machinery.

Authors:  Peter S McPherson; Brigitte Ritter
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

8.  Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking.

Authors:  Martina Metzler; Bo Li; Lu Gan; John Georgiou; Claire-Anne Gutekunst; Yushan Wang; Enrique Torre; Rebecca S Devon; Rosemary Oh; Valerie Legendre-Guillemin; Mark Rich; Christine Alvarez; Marina Gertsenstein; Peter S McPherson; Andras Nagy; Yu Tian Wang; John C Roder; Lynn A Raymond; Michael R Hayden
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

9.  Identification of a family of endocytic proteins that define a new alpha-adaptin ear-binding motif.

Authors:  Brigitte Ritter; Jacynthe Philie; Martine Girard; Elaine C Tung; Francois Blondeau; Peter S McPherson
Journal:  EMBO Rep       Date:  2003-10-10       Impact factor: 8.807

10.  Use of a cryptic splice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues.

Authors:  Chiron W Graves; Steven T Philips; Sarah V Bradley; Katherine I Oravecz-Wilson; Lina Li; Alice Gauvin; Theodora S Ross
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.